Immuron Launches PROIBS® for IBS, Boosts Investor Engagement with Strategic Initiatives
Immuron Limited has launched its new product, PROIBS, a treatment for Irritable Bowel Syndrome (IBS), and is also engaging with investors through a virtual conference, highlighting the company’s expansion into the IBS therapeutic space.
2 minutes to read